Bellerophon Therapeutics Inc. (BLPH) OTC MARKETS
$0.06 - (-)
Market Cap: -
As of 04/30/24 12:00 AM EDT. Market closed.
Bellerophon Therapeutics Inc. (BLPH)
OTC MARKETS
$0.06
- (-)
Market Cap: -
As of 04/30/24 12:00 AM EDT. Market closed.
Add to Portfolio
bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Fabian Tenenbaum
Full Time Employees
27
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Fabian Tenenbaum
Full Time Employees
27
Address
184 Liberty Corner Rd Ste 302, New Jersey, Warren, 07059-6868.
PRICE CHART FOR BELLEROPHON THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$0.30
Previous Close
$0.06
Days Range
$0.06 - $0.06
52 week range
- - -
Volume
14,949,014
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
12,232,648
Open
$0.30
Previous Close
$0.06
Days Range
$0.06 - $0.06
52 week range
- - -
Volume
14,949,014
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
12,232,648
FINANCIAL STATEMENTS FOR BELLEROPHON THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR BELLEROPHON THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Puissance Capital Management LP | 10% Owner | Oct 13, 2023 | Sale | $0.10 | 1,076,841 | 111,776 | 0 | Oct 16, 2023, 08:51 PM |
| Puissance Life Science Opportunities Fund VI | 10% Owner | Jun 07, 2023 | Sale | $0.83 | 134,421 | 111,569 | 1,076,841 | Jun 07, 2023, 09:21 PM |
| Kim Bobae | VP Reg. Affairs & Quality | May 18, 2023 | Option Exercise | $7.47 | 1,288 | 9,620 | 1,723 | May 22, 2023, 06:51 PM |
| Kim Bobae | VP Reg. Affairs & Quality | May 18, 2023 | Sale | $10.00 | 9,455 | 94,550 | 1,723 | May 22, 2023, 06:51 PM |
| Puissance Life Science Opportunities Fund VI | 10% Owner | May 18, 2023 | Sale | $9.46 | 560,000 | 5,297,600 | 1,211,262 | May 19, 2023, 08:55 PM |
| Dekker Martin | VP OF ENGINEERING & MANUFACTUR | Dec 09, 2022 | Option Exercise | $0.93 | 7,834 | 7,286 | 17,666 | Dec 13, 2022, 05:26 PM |
| Shah Parag Suresh | VP OF BUSINESS OPERATIONS | Dec 09, 2022 | Option Exercise | $0.93 | 7,834 | 7,286 | 17,666 | Dec 13, 2022, 05:25 PM |
| Laccona Nicholas | FINANCIAL OFFICER, (PFO & PAO) | Dec 09, 2022 | Option Exercise | $0.93 | 5,530 | 5,143 | 12,470 | Dec 13, 2022, 05:25 PM |
| Fernandes Peter | PRINCIPAL EXECUTIVE OFFICER | Dec 09, 2022 | Option Exercise | $0.93 | 9,985 | 9,287 | 22,515 | Dec 13, 2022, 05:25 PM |
| Puissance Life Science Opportunities Fund VI | 10% Owner | Jun 07, 2021 | Option Exercise | $4.00 | 8,189 | 32,756 | 1,771,262 | Jun 08, 2021, 12:37 PM |
| New Mountain Investments II, LLC | 10% Owner | Mar 18, 2021 | Sale | $5.48 | 400,000 | 2,192,000 | 609,231 | Mar 22, 2021, 09:36 PM |
| FARES Wassim | Chief Medical Officer | Sep 10, 2020 | Buy | $10.18 | 4,000 | 40,708 | 4,000 | Sep 14, 2020, 08:31 AM |
| Wang Theodore T | Director | Jun 08, 2020 | Buy | $12.87 | 2,600 | 33,454 | 60,913 | Jun 09, 2020, 04:01 PM |
| Wang Theodore T | Director | Jun 05, 2020 | Buy | $12.72 | 4,986 | 63,442 | 58,313 | Jun 09, 2020, 04:01 PM |
| Puissance Life Science Opportunities Fund VI | 10% Owner | May 21, 2020 | Option Exercise | $13.00 | 1,153,846 | 14,999,998 | 1,153,846 | May 22, 2020, 07:25 AM |
| Wang Theodore T | Director | Nov 25, 2019 | Buy | $0.39 | 7,193 | 2,774 | 592,922 | Nov 25, 2019, 04:52 PM |
| Wang Theodore T | Director | Nov 22, 2019 | Buy | $0.37 | 1,050 | 394 | 585,729 | Nov 25, 2019, 04:52 PM |
| Wang Theodore T | Director | Nov 21, 2019 | Buy | $0.37 | 200 | 74 | 584,679 | Nov 25, 2019, 04:52 PM |
| Shah Parag Suresh | VP of Business Operations | Nov 15, 2019 | Option Exercise | $0.34 | 25,993 | 8,838 | 105,606 | Nov 19, 2019, 04:36 PM |
| Fernandes Peter | Chief Regulatory & Safety Offr | Nov 15, 2019 | Option Exercise | $0.34 | 40,280 | 13,695 | 182,022 | Nov 19, 2019, 04:36 PM |
| Tenenbaum Fabian | Chief Executive Officer | Nov 15, 2019 | Option Exercise | $0.34 | 76,823 | 26,120 | 407,459 | Nov 19, 2019, 04:36 PM |
| Dekker Martin | VP of Engineering & Manuf | Nov 15, 2019 | Option Exercise | $0.34 | 27,134 | 9,226 | 124,619 | Nov 19, 2019, 04:35 PM |
| Korner Assaf | CFO | Nov 15, 2019 | Option Exercise | $0.34 | 32,987 | 11,216 | 66,078 | Nov 19, 2019, 04:35 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 24, 2019 | Sale | $0.50 | 704,595 | 353,354 | 6,824,425 | Oct 28, 2019, 05:17 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 28, 2019 | Sale | $0.44 | 333,010 | 146,091 | 6,435,173 | Oct 28, 2019, 05:17 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 25, 2019 | Sale | $0.45 | 56,242 | 25,511 | 6,768,183 | Oct 28, 2019, 05:17 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 28, 2019 | Sale | $0.44 | 333,010 | 146,091 | 6,435,173 | Oct 28, 2019, 05:15 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 25, 2019 | Sale | $0.45 | 56,242 | 25,511 | 6,768,183 | Oct 28, 2019, 05:15 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 24, 2019 | Sale | $0.50 | 704,595 | 353,354 | 6,824,425 | Oct 28, 2019, 05:15 PM |
| Wang Theodore T | Director | Jun 12, 2019 | Buy | $0.64 | 50,000 | 31,905 | 584,479 | Jun 14, 2019, 11:46 AM |
| Wang Theodore T | Director | May 22, 2019 | Buy | $0.60 | 27,500 | 16,533 | 534,479 | May 24, 2019, 09:30 AM |
| Edmonds Amy | VP Clinical Operations & Admin | May 22, 2019 | Option Exercise | $0.61 | 35,827 | 21,797 | 140,216 | May 23, 2019, 04:46 PM |
| Wang Theodore T | Director | May 21, 2019 | Buy | $0.61 | 43,280 | 26,371 | 506,979 | May 22, 2019, 11:15 AM |
| Peacock Jonathan M | Director | May 21, 2019 | Buy | $0.61 | 20,000 | 12,198 | 1,875,920 | May 22, 2019, 11:14 AM |
| Tenenbaum Fabian | Chief Executive Officer | May 21, 2019 | Buy | $0.60 | 5,000 | 2,975 | 484,282 | May 22, 2019, 11:14 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Jan 23, 2019 | Buy | $0.70 | 142,857 | 100,000 | 7,529,020 | Mar 14, 2019, 05:57 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Jan 23, 2019 | Buy | $0.70 | 142,857 | 100,000 | 7,529,020 | Mar 14, 2019, 05:51 PM |
| Wang Theodore T | Director | Jan 25, 2019 | Buy | $0.70 | 450,000 | 315,000 | 463,699 | Jan 25, 2019, 04:22 PM |
| Peacock Jonathan M | Director | Jan 25, 2019 | Buy | $0.70 | 714,286 | 500,000 | 1,855,920 | Jan 25, 2019, 04:21 PM |
| Amin Naseem | Director | Jan 25, 2019 | Buy | $0.70 | 571,429 | 400,000 | 1,818,867 | Jan 25, 2019, 04:12 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 17, 2018 | Buy | $1.18 | 60,000 | 70,944 | 7,386,163 | Sep 17, 2018, 04:46 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 14, 2018 | Buy | $1.23 | 75,000 | 92,250 | 7,326,163 | Sep 17, 2018, 04:46 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 13, 2018 | Buy | $1.19 | 75,000 | 89,160 | 7,251,163 | Sep 17, 2018, 04:46 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 17, 2018 | Buy | $1.18 | 60,000 | 70,944 | 7,386,163 | Sep 17, 2018, 04:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 14, 2018 | Buy | $1.23 | 75,000 | 92,250 | 7,326,163 | Sep 17, 2018, 04:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 13, 2018 | Buy | $1.19 | 75,000 | 89,160 | 7,251,163 | Sep 17, 2018, 04:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 12, 2018 | Buy | $1.15 | 75,000 | 85,912 | 7,176,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 11, 2018 | Buy | $1.14 | 200,000 | 228,840 | 7,101,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 10, 2018 | Buy | $1.22 | 200,000 | 243,640 | 6,901,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 12, 2018 | Buy | $1.15 | 75,000 | 85,912 | 7,176,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 11, 2018 | Buy | $1.14 | 200,000 | 228,840 | 7,101,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 10, 2018 | Buy | $1.22 | 200,000 | 243,640 | 6,901,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 07, 2018 | Buy | $0.90 | 60,000 | 53,742 | 6,701,163 | Sep 07, 2018, 05:45 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 06, 2018 | Buy | $0.84 | 50,000 | 42,095 | 6,641,163 | Sep 07, 2018, 05:45 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 05, 2018 | Buy | $0.85 | 50,000 | 42,325 | 6,591,163 | Sep 07, 2018, 05:45 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 07, 2018 | Buy | $0.90 | 60,000 | 53,742 | 6,701,163 | Sep 07, 2018, 05:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 06, 2018 | Buy | $0.84 | 50,000 | 42,095 | 6,641,163 | Sep 07, 2018, 05:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 05, 2018 | Buy | $0.85 | 50,000 | 42,325 | 6,591,163 | Sep 07, 2018, 05:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 15, 2018 | Buy | $0.65 | 272,000 | 175,902 | 6,474,770 | Aug 16, 2018, 07:33 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 14, 2018 | Buy | $0.65 | 190,977 | 123,868 | 6,202,770 | Aug 16, 2018, 07:33 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 16, 2018 | Buy | $0.65 | 66,393 | 43,109 | 6,541,163 | Aug 16, 2018, 07:33 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 16, 2018 | Buy | $0.65 | 66,393 | 43,109 | 6,541,163 | Aug 16, 2018, 07:31 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 15, 2018 | Buy | $0.65 | 272,000 | 175,902 | 6,474,770 | Aug 16, 2018, 07:31 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 14, 2018 | Buy | $0.65 | 190,977 | 123,868 | 6,202,770 | Aug 16, 2018, 07:31 PM |
| Quinn Deborah | Chief Medical Officer | Jun 12, 2018 | Option Exercise | $2.37 | 10,541 | 24,982 | 94,070 | Jun 14, 2018, 04:42 PM |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | Jun 12, 2018 | Option Exercise | $2.37 | 7,144 | 16,931 | 53,094 | Jun 14, 2018, 04:41 PM |
| Edmonds Amy | VP Clinical Operations & Admin | Jun 12, 2018 | Option Exercise | $2.37 | 7,499 | 17,773 | 93,800 | Jun 14, 2018, 04:40 PM |
| Tenenbaum Fabian | Chief Executive Officer | Jun 12, 2018 | Option Exercise | $2.37 | 63,486 | 150,462 | 254,983 | Jun 14, 2018, 04:39 PM |
| Fernandes Peter | Chief Regulatory & Safety Offr | Jun 12, 2018 | Option Exercise | $2.37 | 11,304 | 26,790 | 102,676 | Jun 14, 2018, 04:37 PM |
| Dekker Martin | VP of Engineering & Manuf | Jun 12, 2018 | Option Exercise | $2.37 | 7,473 | 17,711 | 69,510 | Jun 14, 2018, 04:35 PM |
| Fernandes Peter | Chief Regulatory & Safety Offr | Jan 04, 2018 | Option Exercise | $2.49 | 35,321 | 87,949 | 82,453 | Jan 08, 2018, 05:26 PM |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | Jan 04, 2018 | Option Exercise | $2.49 | 23,180 | 57,718 | 39,548 | Jan 08, 2018, 04:52 PM |
| Dekker Martin | VP of Engineering & Manuf | Jan 04, 2018 | Option Exercise | $2.49 | 24,284 | 60,467 | 55,308 | Jan 08, 2018, 04:49 PM |
| Quinn Deborah | Chief Medical Officer | Jan 04, 2018 | Option Exercise | $2.49 | 33,114 | 82,454 | 75,054 | Jan 08, 2018, 04:46 PM |
| Schoeps Megan | Principal Financial Officer | Dec 13, 2017 | Option Exercise | $0.49 | 1,000 | 490 | 19,248 | Dec 13, 2017, 04:36 PM |
| Schoeps Megan | Principal Financial Officer | May 17, 2017 | Option Exercise | $1.40 | 10,459 | 14,683 | 18,248 | May 19, 2017, 04:04 PM |
| Luehring Jens | Director | Dec 09, 2016 | Buy | $0.56 | 20,000 | 11,200 | 39,860 | Dec 12, 2016, 10:10 AM |
| Quinn Deborah | Chief Medical Officer | Sep 12, 2016 | Option Exercise | $1.38 | 18,548 | 25,596 | 31,244 | Sep 13, 2016, 08:21 PM |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | Sep 12, 2016 | Option Exercise | $1.38 | 4,673 | 6,449 | 8,881 | Sep 13, 2016, 08:18 PM |
| Dekker Martin | VP of Device Engineering | Sep 12, 2016 | Option Exercise | $1.38 | 13,333 | 18,400 | 23,181 | Sep 13, 2016, 08:16 PM |
| Edmonds Amy | VP Clinical Operations & Admin | Sep 12, 2016 | Option Exercise | $1.38 | 13,301 | 18,355 | 23,213 | Sep 13, 2016, 08:14 PM |
| Fernandes Peter | Chief Regulatory Officer | Sep 12, 2016 | Option Exercise | $1.38 | 19,785 | 27,303 | 35,722 | Sep 13, 2016, 08:11 PM |
| Peacock Jonathan M | President and CEO | May 17, 2016 | Buy | $1.37 | 5,000 | 6,841 | 222,702 | May 18, 2016, 01:46 PM |
| Peacock Jonathan M | President and CEO | Dec 16, 2015 | Buy | $2.76 | 12,800 | 35,336 | 51,727 | Dec 17, 2015, 05:01 PM |
| Peacock Jonathan M | President and CEO | Dec 15, 2015 | Buy | $2.72 | 7,500 | 20,400 | 38,927 | Dec 17, 2015, 05:01 PM |
| Peacock Jonathan M | President and CEO | Aug 19, 2015 | Buy | $5.48 | 5,000 | 27,377 | 31,427 | Aug 20, 2015, 05:34 PM |
| MEGLASSON MARTIN | Chief Scientific Officer | May 20, 2015 | Buy | $8.40 | 712 | 5,981 | 19,098 | May 22, 2015, 07:32 AM |
| Peacock Jonathan M | President and CEO | May 20, 2015 | Buy | $8.69 | 5,560 | 48,323 | 26,427 | May 22, 2015, 07:32 AM |
| ARCH VENTURE FUND VI LP | 10% Owner | Feb 19, 2015 | Buy | $12.00 | 212,666 | 2,551,992 | 965,660 | Feb 23, 2015, 09:48 PM |
| NELSEN ROBERT | Director | Feb 19, 2015 | Buy | $12.00 | 212,666 | 2,551,992 | 965,660 | Feb 23, 2015, 09:47 PM |
| New Mountain Investments II, LLC | 10% Owner | Feb 19, 2015 | Buy | $12.00 | 1,070,166 | 12,841,992 | 4,859,885 | Feb 23, 2015, 09:47 PM |
| Weinstein Adam | Director | Feb 19, 2015 | Buy | $12.00 | 1,070,166 | 12,841,992 | 4,859,885 | Feb 23, 2015, 09:47 PM |
| Holt Matthew S. | Director | Feb 19, 2015 | Buy | $12.00 | 1,070,166 | 12,841,992 | 4,859,885 | Feb 23, 2015, 09:46 PM |
| Linde North America, Inc. | 10% Owner | Feb 19, 2015 | Buy | $12.00 | 358,916 | 4,306,992 | 1,629,804 | Feb 23, 2015, 09:41 PM |
| Luehring Jens | Director | Feb 19, 2015 | Buy | $12.00 | 358,916 | 4,306,992 | 1,629,804 | Feb 23, 2015, 09:41 PM |
| Tasse Daniel | Director | Feb 19, 2015 | Buy | $12.00 | 25,000 | 300,000 | 128,898 | Feb 23, 2015, 09:41 PM |
| Heyrman Reinilde | Chief Clinical Dev. Officer | Feb 19, 2015 | Buy | $12.00 | 1,500 | 18,000 | 9,483 | Feb 23, 2015, 09:40 PM |
| MEGLASSON MARTIN | Chief Scientific Officer | Feb 19, 2015 | Buy | $12.00 | 12,000 | 144,000 | 18,386 | Feb 23, 2015, 09:39 PM |
| Naidu Manesh | Chief Business Officer | Feb 19, 2015 | Buy | $12.00 | 1,500 | 18,000 | 11,319 | Feb 23, 2015, 09:39 PM |
| Peacock Jonathan M | President and CEO | Feb 19, 2015 | Buy | $12.00 | 20,800 | 249,600 | 20,867 | Feb 23, 2015, 09:39 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING FOR BELLEROPHON THERAPEUTICS INC
STOCK BUYBACKS FOR BELLEROPHON THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 06/30/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2023
15.33%
1Q
12/31/2022
27.85%
2Q
09/30/2022
28.14%
3Q
06/30/2022
28.14%
4Q
03/31/2022
28.14%
5Q
12/31/2021
28.66%
6Q
09/30/2021
28.67%
7Q
06/30/2021
28.67%
8Q
03/31/2021
28.87%
9Q
09/30/2020
28.88%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR BELLEROPHON THERAPEUTICS INC
LOADING...